Immunomodulation at maternal-fetal interface

Immunomodulation at the maternal-fetal interface refers to the network of biological processes that establish immune tolerance between mother and fetus, allowing the semi-allogeneic fetus to escape maternal immune rejection while maintaining protection against pathogens. This occurs through an interplay of trophoblasts, various maternal immune cells (such as regulatory T cells, decidual natural killer cells, macrophages), immune checkpoint molecules, and microbiota. Abnormalities in these immunomodulatory mechanisms are linked to pregnancy complications, such as pre-eclampsia and miscarriage. While molecular targets within this system (such as PD-1/PD-L1 or Treg cells) may serve as therapeutic targets, “immunomodulation at maternal-fetal interface” itself is a broad conceptual term, not a single molecule or receptor

Other names

Maternal-fetal immunomodulationImmune tolerance at maternal-fetal interfaceFetomaternal immune regulation

drugs may act by enhancing regulatory T cell activity or altering immune checkpoint molecules like PD-1/PD-L1, but specifics depend on the molecular targets involved